The radiological response of patients with advanced bone metastases to lutetium-177-labeled DOTA-ibandronic acid assessed by metabolic tumor volume.
Saved in:
| Title: | The radiological response of patients with advanced bone metastases to lutetium-177-labeled DOTA-ibandronic acid assessed by metabolic tumor volume. |
|---|---|
| Authors: | Yang J; Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, No. 25 TaiPing St, Jiangyang District, Luzhou, 646000, Sichuan, People's Republic of China.; Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan, People's Republic of China.; Academician (Expert) Workstation of Sichuan Province, Luzhou, People's Republic of China., Zhang L; Department of Neurosurgery, The Affiliated Hospital, Southwest Medical University, Luzhou, People's Republic of China.; Laboratory of Neurological Diseases and Brain Function, The Affiliated Hospital, Southwest Medical University, Luzhou, People's Republic of China., Chen Y; Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, No. 25 TaiPing St, Jiangyang District, Luzhou, 646000, Sichuan, People's Republic of China. chenyue5523@126.com.; Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan, People's Republic of China. chenyue5523@126.com.; Academician (Expert) Workstation of Sichuan Province, Luzhou, People's Republic of China. chenyue5523@126.com. |
| Source: | Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2025 Jul 10; Vol. 151 (7), pp. 210. Date of Electronic Publication: 2025 Jul 10. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-1335 (Electronic) Linking ISSN: 01715216 NLM ISO Abbreviation: J Cancer Res Clin Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
